Quantinuum Inc. (QNT) is a Broomfield, Colorado-based quantum computing company that develops trapped-ion hardware, middleware, and software. Eleven recent, attributable analyst targets were reviewed, spanning roughly $50 to $80 and averaging about $60.60, which rounds to a $60 central target. The Street's posture is broadly bullish — coverage skews to Buy or Overweight ratings with no Sell ratings in the recent set — but the targets tell a more nuanced story.
After the company's third-quarter results, several firms cut targets sharply while keeping bullish ratings. Morgan Stanley's Joseph Moore reiterated Buy and trimmed the target from $62 to $57; JPMorgan's Harlan Sur kept Buy but lowered from $97 to $80; UBS's David Vogt cut from $93 to $50; Jefferies's Kevin Garrigan cut from $85 to $65; and Craig-Hallum's Richard Shannon reduced from $100 to $60. Cantor Fitzgerald moved its target from $90 to $55, while BofA Securities and BTIG carry $50 and $60 targets respectively. The $50-to-$80 range signals that analysts agree on the company's long-term potential but disagree materially on near-term commercialization timing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
As of mid-November 2026, QNT trades near $33.80, down sharply from its 52-week high of $86.79 and only modestly above its 52-week low of $28.31. Reaching $60 would require a gain of about 78%, a very large move that would only retrace a portion of the stock's decline from its post-IPO peak.
The company completed its initial public offering in June 2026, and the shares have traded in a wide range since. Quantinuum reported third-quarter net revenue of $9.1 million, up 233% year over year, and ended the period with roughly $1.9 billion in cash — a meaningful cushion relative to its current operating losses. The company also secured a $100 million award under the U.S. CHIPS Act. These factors provide a foundation, but the stock's negative momentum and heavy losses mean any path toward $60 likely depends on sustained revenue acceleration and clearer evidence of commercial adoption rather than valuation alone.
The 52-week range of $28.31 to $86.79 frames the stock's volatility. The $28.31 low, set in early November 2026, is the nearest key support level; a sustained break below it would signal further downside. On the upside, the $50 area is a notable resistance zone, both because it is a psychological round-number level and because several analyst targets (UBS and BofA Securities at $50, Cantor Fitzgerald at $55) sit just above it. The $60 target therefore implies clearing this $50-to-$55 band first, with no meaningful technical support between the current price and that zone.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may use longer frameworks given the early stage of quantum commercialization. Investors should watch quarterly revenue growth and the pace of commercial bookings, cash burn and any financing activity, the CHIPS Act award's implementation, and further analyst revisions after each earnings report. Macroeconomic conditions, particularly interest-rate expectations, matter for a pre-profit growth name. The next earnings report and any subsequent target changes will be the clearest near-term signposts. From what I see, this is important because timing remains uncertain in this sector.
In my view, AI tools have become a practical part of my routine when analyzing volatile names like this one. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals as market conditions, technical behavior, and AI-driven analysis shift. For a momentum-sensitive stock, these signals can help surface opportunities and identify changing trends more efficiently than manual screening alone.
Can Quantinuum reach $60? The target, derived from the average of 11 recent analyst price targets, sits about 78% above the current price and implies a substantial recovery from the stock's deep drawdown. Support comes from a strong cash position, rapid revenue growth from a small base, notable hardware achievements, and government backing. Against that, heavy losses, commercialization uncertainty, aggressive downward target revisions, and weak technical structure are meaningful obstacles. The wide $50-to-$80 analyst range underscores genuine disagreement about timing. The target is best understood as a 12-month aspiration contingent on accelerating adoption, not a near-term certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for QNT moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 1 similar instances when the indicator left oversold territory. In 1 of the 1 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +14.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where QNT advanced for three days, in 9 of 9 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
QNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QNT as a result. In 4 of 4 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QNT turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 2 similar instances when the indicator turned negative. In 2 of the 2 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for QNT entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.571) is normal, around the industry mean (-1.922). P/E Ratio (-27.402) is within average values for comparable stocks, (9.599). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.071) among similar stocks. P/S Ratio (81.967) is also within normal values, averaging (71.013).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. QNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PackagedSoftware